EpiCypher®, a leader in epigenomics innovation, announces the launch of CUTANA® meCUT&RUN and Multiomic CUT&RUN, two novel DNA methylation sequencing technologies advancing the frontiers of genomic research and drug discovery.
These tools build upon EpiCypher’s proven CUT&RUN platform – a targeted nuclease strategy that has revolutionized chromatin profiling by enabling high-resolution mapping from ultra-low inputs and with reduced sequencing costs. CUT&RUN has broadly supplanted traditional ChIP-seq, powering discoveries across development, disease, and therapeutic research.
DNA methylation is a critical epigenetic mechanism that regulates gene expression, genomic imprinting, and cell identity. Bisulfite sequencing, the traditional gold-standard method for mapping 5-methylcytosine (5mC), suffers from multiple limitations including DNA degradation, excessive sequencing costs, high cell input requirements, making it difficult to integrate with other epigenomic workflows.
CUTANA® meCUT&RUN directly extends the CUT&RUN core platform to DNA methylation by leveraging a novel methyl-DNA binding fusion protein that enriches 5mC with exceptional specificity. With base-pair resolution, this approach is capable of detecting >80% of methyl-CpGs captured by whole-genome approaches while using >20 times less sequencing, setting a new standard for scalable, low-cost DNA methylation analysis.
Building on this innovation, the CUTANA® Multiomic CUT&RUN assay offers researchers the unprecedented ability to co-profile chromatin features (e.g., histone modifications or DNA-binding proteins) alongside DNA methylation. Such simultaneous capture uncovers the dynamic relationship between two fundamental layers of epigenetic regulation – unlocking critical insights for foundational research and translational drug discovery.
“With meCUT&RUN and Multiomic CUT&RUN, we’re providing researchers with highly sensitive, scalable tools to reveal and decode complex mechanisms for gene regulation,” said Dr. Michael-Christopher Keogh, Chief Scientific Officer at EpiCypher. “These technologies mark a dramatic leap forward in resolving how DNA methylation and chromatin states intersect in development and disease.”
Key Benefits of CUTANA® meCUT&RUN:
Key Benefits of CUTANA® Multiomic CUT&RUN:
“Today, most DNA methylation studies rely on targeted approaches – not by choice, but out of necessity – due to the high costs of whole-genome methods,” said Martis Cowles, Chief Business Officer at EpiCypher. “Our drive was to bridge that gap. These new products deliver genome-wide insights using a targeted, cost-efficient approach, bringing comprehensive methylation analysis within reach for a broader range of researchers and applications.” meCUT&RUN and Multiomic CUT&RUN are now available to academic, biotech, and pharmaceutical researchers pursuing discovery in cancer biology, neuroscience, immunology, aging, and beyond.
For more information about EpiCypher Inc. and their breakthrough research technologies, please visit www.epicypher.com
About EpiCypher Inc.
EpiCypher was founded in response to the growing demand for high-quality reagents to study chromatin regulation and enable epigenetics-focused drug discovery. The Company is at the forefront of chromatin mapping technologies with the CUTANA® platform for ultra-sensitive genomic profiling assays, including CUT&RUN and CUT&Tag. EpiCypher also offers the largest collection of defined designer nucleosomes (dNucs) on the market along with complementary high-throughput assays and services. EpiCypher is dedicated to bringing these transformative technologies to market and offers superior products and assay services to researchers worldwide.
EpiCypher® and CUTANA® are registered trademarks of EpiCypher, Inc.